Ryohei Katayama
机构: Japanese Foundation for Cancer Research
每年引用次数
引用次数
引用: 14,850
H-指数: 42
I10-指数 : 63
出版物: 172
[Clinical evaluation of enzyme immuno assay systems for HCV antibody--synthetic peptide antigen and recombinant antigen].
Tanaka Y , Iwata Y , Katayama R , Irishio H
The Japanese journal of clinical pathology 43 ( 7) 686 -690
1995
Influence of Cu distribution on photocatalytic activity of Cu-doped titania prepared using metal alkoxides
Hiromasa Nishikiori , Tomoaki Ikeda , Yuki Izaki , Ryuhei Katayama
Research on Chemical Intermediates 42 ( 5) 4813 -4825
3
2016
Resistance mechanisms to tyrosine kinase inhibitor in ROS1 or NTRK rearranged cancer.
KOTARO OKADA , RYOHEI KATAYAMA
月刊腫瘍内科 25 ( 5) 547 -551
2020
Resistance to anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) in patients with lung cancer: Single mutations, compound mutations, and other mechanisms of drug resistance
Ryohei Katayama , Ryohei Katayama
Academic Press 87 -99
2021
Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer.
Mutsuko Kukimoto-Niino , Ryohei Katayama , Ryohei Katayama , Siro Simizu
Nature Communications 12 ( 1) 1261 -1261
35
2021
Novel knock-in mouse model for the evaluation of the therapeutic efficacy and toxicity of human podoplanin-targeting agents.
Ryohei Katayama , Satoshi Takagi , Naoya Fujita , Ai Takemoto
Cancer Science 112 ( 6) 2299 -2313
2021
A case of hyperprogressive disease following atezolizumab therapy for pulmonary pleomorphic carcinoma with epidermal growth factor receptor mutation.
Ryohei Katayama , Shigemichi Hirose , Kota Ishioka , Saeko Takahashi
Respiratory medicine case reports 33 101405 -101405
2021
Microsecond-timescale MD simulation of EGFR minor mutation predicts the structural flexibility of EGFR kinase core that reflects EGFR inhibitor sensitivity.
Ryohei Katayama , Kengo Takeuchi , Satoshi Takagi , Naoya Fujita
npj Precision Oncology 5 ( 1) 32 -32
2021
Chromatin structure-dependent histone incorporation revealed by a genome-wide deposition assay.
Hitoshi Kurumizaka , Ryohei Katayama , Yasuyuki Ohkawa , Noriko Saitoh
eLife 10
2021
APC Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer.
Noritaka Tanaka , Tetsuo Mashima , Anna Mizutani , Ayana Sato
Molecular Cancer Therapeutics 16 ( 4) 752 -762
37
2017
Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers.
Miho J. Fuse , Koutaroh Okada , Tomoko Oh-hara , Hayato Ogura
Molecular Cancer Therapeutics 16 ( 10) 2130 -2143
42
2017
Cell-permeable Carboxyl-terminal p27Kip1 Peptide Exhibits Anti-tumor Activity by Inhibiting Pim-1 Kinase,
Daisuke Morishita , Miho Takami , Seiko Yoshikawa , Ryohei Katayama
Journal of Biological Chemistry 286 ( 4) 2681 -2688
19
2011
Abstract LB-123: Identification of the molecular mechanisms of resistance to NTRK inhibitors and the potential therapeutic strategies in NTRK1-rearranged cancers
Ryohei Katayama , Miho J. Fuse , Tomoko Oh-hara , Hayato Ogura
Cancer Research 77
2017
Abstract B02: Heterogeneity of epithelial-to-mesenchymal transition and resistance mutation in ALK inhibitor-resistant lung cancer and its circumvention
Koji Fukuda , Shinji Takeuchi , Sachiko Arai , Ryohei Katayama
Clinical Cancer Research 24
2018
Therapeutic strategies and mechanisms of drug resistance in anaplastic lymphoma kinase (ALK)-rearranged lung cancer.
Ryohei Katayama
Pharmacology & Therapeutics 177 1 -8
18
2017
A unique ex vivo tumor model: 3D cocultured system with cancer and stromal cells including blood microvessels.
Yuki Takahashi , Kei Tsukamoto , Rii Morimura , Isana Nada
Journal of Clinical Oncology 38 211 -211
2020
TUSC4/NPRL2, a novel PDK1-interacting protein, inhibits PDK1 tyrosine phosphorylation and its downstream signaling
Atsuo Kurata , Ryohei Katayama , Toshiki Watanabe , Takashi Tsuruo
Cancer Science 99 ( 9) ??? -???
26
2008
Dofequidar fumarate sensitizes cancer stem-like side population cells to chemotherapeutic drugs by inhibiting ABCG2/BCRP-mediated drug export.
Ryohei Katayama , Sumie Koike , Shigeo Sato , Yoshikazu Sugimoto
Cancer Science 100 ( 11) 2060 -2068
61
2009
Pim Kinases Promote Cell Cycle Progression by Phosphorylating and Down-regulating p27Kip1 at the Transcriptional and Posttranscriptional Levels
Daisuke Morishita , Ryohei Katayama , Kazuhisa Sekimizu , Takashi Tsuruo
Cancer Research 68 ( 13) 5076 -5085
215
2008
Tivantinib (ARQ 197) Exhibits Antitumor Activity by Directly Interacting with Tubulin and Overcomes ABC Transporter–Mediated Drug Resistance
Aki Aoyama , Ryohei Katayama , Tomoko Oh-hara , Shigeo Sato
Molecular Cancer Therapeutics 13 ( 12) 2978 -2990
55
2014